---
figid: PMC4846800__fcell-04-00033-g0002
figlink: /pmc/articles/PMC4846800/figure/F2/
number: F2
caption: Resistance mechanisms in MAPK-inhibitor treated melanoma. Resistance to BRAF
  inhibitors can occur through activating NRAS mutations (*), loss of the RAS suppressor
  NF1, BRAF amplification or alternative splicing leading to BRAF truncations (semicircles
  B*), overexpression or mutation of the MEK activators CRAF, COT/TPL2/MAP3K8 or MLKs
  as well as MEK mutations (*). Addition of a MEK inhibitor can buffer some of these
  resistance mechanisms, but eventually enhanced resistance signaling will overcome
  its effects. While ERK is inhibited -particularly in the initial phases of treatment-
  MITF expression is up-regulated and contributes to drug-tolerance. Solid arrows
  indicate signaling induced by mutant BRAF, dashed arrows indicate signaling brought
  about by the various resistance mechanisms.
pmcid: PMC4846800
papertitle: The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma
  Skin Cancer.
reftext: Claudia Wellbrock, et al. Front Cell Dev Biol. 2016;4:33.
pmc_ranked_result_index: '62829'
pathway_score: 0.9436599
filename: fcell-04-00033-g0002.jpg
figtitle: Resistance mechanisms in MAPK-inhibitor treated melanoma
year: '2016'
organisms:
- Homo sapiens
ndex: 9ab33e14-debb-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4846800__fcell-04-00033-g0002.html
  '@type': Dataset
  description: Resistance mechanisms in MAPK-inhibitor treated melanoma. Resistance
    to BRAF inhibitors can occur through activating NRAS mutations (*), loss of the
    RAS suppressor NF1, BRAF amplification or alternative splicing leading to BRAF
    truncations (semicircles B*), overexpression or mutation of the MEK activators
    CRAF, COT/TPL2/MAP3K8 or MLKs as well as MEK mutations (*). Addition of a MEK
    inhibitor can buffer some of these resistance mechanisms, but eventually enhanced
    resistance signaling will overcome its effects. While ERK is inhibited -particularly
    in the initial phases of treatment- MITF expression is up-regulated and contributes
    to drug-tolerance. Solid arrows indicate signaling induced by mutant BRAF, dashed
    arrows indicate signaling brought about by the various resistance mechanisms.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CDK4
  - MITF
  - RAF1
  - BRAF
  - KRAS
  - CDK2
  - CROT
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - BCL2A1
  - HRAS
  - NRAS
  - EIF2AK3
  - ARAF
  - NF1
  - trametinib
  - dabrafenib
  - cobimetinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: CDK2,CDK4
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: MITF
  symbol: MITF
  source: hgnc_symbol
  hgnc_symbol: MITF
  entrez: '4286'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: (BRAF*
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAS*
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: CDK2,CDK4
  symbol: CDK2
  source: hgnc_symbol
  hgnc_symbol: CDK2
  entrez: '1017'
- word: COT
  symbol: COT
  source: hgnc_alias_symbol
  hgnc_symbol: CROT
  entrez: '54677'
- word: (MEK*
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: (MEK*
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: BCL2A1
  symbol: BCL2A1
  source: hgnc_symbol
  hgnc_symbol: BCL2A1
  entrez: '597'
- word: RAS*
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS*
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: P-ERK
  symbol: PERK
  source: hgnc_alias_symbol
  hgnc_symbol: EIF2AK3
  entrez: '9451'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: NF1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
chemicals:
- word: trametinib
  source: MESH
  identifier: C560077
- word: dabrafenib
  source: MESH
  identifier: C561627
- word: cobimetinib
  source: MESH
  identifier: C574276
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4846800__F2
redirect_from: /figures/PMC4846800__F2
figtype: Figure
---
